A large national survey of over 735,000 U.S. adults found that obese individuals were roughly 35% less likely to report current marijuana use than non-obese adults, a pattern consistent across demographic groups and multiple years. However, because the study is cross-sectional and relies on self-reported data, it cannot tell us whether marijuana use actually reduces obesity or whether other factors explain the association.

Obesity affects over 40% of American adults and remains one of the most intractable public health challenges in the country, while marijuana use has surged to historically high levels as legalization spreads. Patients and clinicians increasingly encounter claims that cannabis may help with weight management, making it essential to understand what population-level data actually shows. With over 735,000 survey respondents across seven years, this study provides one of the most comprehensive looks at whether marijuana users and obese adults overlap in ways that suggest a meaningful biological or behavioral relationship.

Obesity and marijuana use are both increasing in prevalence across the United States, and preclinical research has suggested that certain cannabinoids may influence energy metabolism, appetite regulation, and fat storage through the endocannabinoid system. Against this backdrop, investigators analyzed data from the Behavioral Risk Factor Surveillance System (BRFSS), the nation’s largest ongoing telephone health survey, drawing on seven years of responses (2016 through 2022) from the optional marijuana use module. The study used survey-weighted logistic regression to examine whether obese adults (BMI of 30 or greater) differed from non-obese adults in their likelihood of reporting current or daily marijuana use, adjusting for age, sex, race and ethnicity, education, income, employment, smoking history, legalization status, and selected medical conditions.

The headline findings are striking in their consistency. Marijuana use prevalence among U.S. adults roughly doubled from 7.48% in 2016 to 14.91% in 2022, closely tracking the expansion of state legalization. Prevalence was roughly 81% higher in recreationally legal states compared to non-legal states. Obese adults were consistently less likely to report marijuana use, with adjusted odds ratios of approximately 0.68 for current use and 0.69 for daily use, a pattern that held across demographic subgroups and showed a dose-response-like gradient as BMI category increased from normal weight through overweight to obese. However, the cross-sectional design cannot establish temporality or causation, self-reported BMI and drug use are known to introduce systematic measurement error, and incomplete state participation in the optional module varied year to year. The authors acknowledge that prospective longitudinal studies are needed before any causal claims can be supported.

This study does something genuinely useful: it gives us a current, large-scale empirical snapshot of how marijuana use and obesity overlap in the real world. The consistency of the inverse association across subgroups and the dose-response gradient across BMI categories are interesting signals that something biologically plausible might be happening. That said, the gap between “obese adults are less likely to use marijuana” and “marijuana helps with weight loss” is enormous, and I worry that headlines derived from studies like this will push patients toward cannabis as a metabolic intervention without evidence that it works in that capacity.

In my practice, I see patients who are curious about whether cannabis might help with weight management, and I take those conversations seriously. I explain that the association is real but unexplained, and that many plausible explanations have nothing to do with a direct metabolic effect. I focus on comprehensive metabolic care, sleep optimization, dietary guidance, and movement, and if cannabis fits into a patient’s broader wellness picture for pain, anxiety, or sleep, we discuss it on those terms rather than as a weight-loss strategy.

This study sits early in the research arc for any clinical application linking cannabis to metabolic health. While the endocannabinoid system is genuinely involved in appetite regulation, lipid metabolism, and insulin sensitivity, population-level associations cannot substitute for the interventional evidence that would be required to recommend cannabis for weight management. Clinicians should understand that the observed inverse association may reflect confounding by lifestyle factors, social patterns, or reverse causation, where leaner and younger individuals may simply be more likely to use marijuana for reasons unrelated to its metabolic effects.

From a pharmacological standpoint, cannabis is a complex botanical product with variable cannabinoid profiles. THC is well known to stimulate appetite acutely, which would seem to contradict the hypothesis that marijuana use reduces body weight. Some researchers have speculated that THCV, CBD, or chronic downregulation of CB1 receptors may counteract this effect, but these mechanisms remain largely speculative in humans. Cannabis also interacts with medications commonly prescribed to obese patients, including certain antihypertensives, antidiabetic agents, and psychiatric medications. The single most actionable recommendation from this data is that clinicians should not extrapolate these survey-level associations into individualized metabolic guidance, and should instead wait for controlled trial evidence before considering cannabis as part of obesity management.

Have thoughts on this? Share it: